Synergistic immunostimulatory effects and therapeutic benefit of combined histone deacetylase and bromodomain inhibition in non–small cell lung cancer

Dennis O. Adeegbe, Yan Liu, Patrick H. Lizotte, Ysusuke Kamihara, Amir R. Aref, Christina Almonte, Ruben Dries, Yuyang Li, Shengwu Liu, Xiaoen Wang, Tiquella Warner-Hatten, Jessica Castrillon, Guo Cheng Yuan, Neermala Poudel-Neupane, Haikuo Zhang, Jennifer L. Guerriero, Shiwei Han, Mark M. Awad, David A. Barbie, Jerome RitzSimon S. Jones, Peter S. Hammerman, James Bradner, Steven N. Quayle, Kwok Kin Wong

Research output: Contribution to journalArticlepeer-review

117 Scopus citations

Abstract

Effective therapies for non–small cell lung cancer (NSCLC) remain challenging despite an increasingly comprehensive understanding of somatically altered oncogenic pathways. It is now clear that therapeutic agents with potential to impact the tumor immune microenvironment potentiate immune-orchestrated therapeutic benefit. Herein, we evaluated the immunoregulatory properties of histone deacetylase (HDAC) and bromodomain inhibitors, two classes of drugs that modulate the epigenome, with a focus on key cell subsets that are engaged in an immune response. By evaluating human peripheral blood and NSCLC tumors, we show that the selective HDAC6 inhibitor ricolinostat promotes phenotypic changes that support enhanced T-cell activation and improved function of antigen-presenting cells. The bromodomain inhibitor JQ1 attenuated CD4+FOXP3+ T regulatory cell suppressive function and synergized with ricolinostat to facilitate immune-mediated tumor growth arrest, leading to prolonged survival of mice with lung adenocarcinomas. Collectively, our findings highlight the immunomodulatory effects of two epigenetic modifiers that, together, promote T cell–mediated antitumor immunity and demonstrate their therapeutic potential for treatment of NSCLC. SIGNIFICANCE: Selective inhibition of HDACs and bromodomain proteins modulates tumor-associated immune cells in a manner that favors improved T-cell function and reduced inhibitory cellular mechanisms. These effects facilitated robust antitumor responses in tumor-bearing mice, demonstrating the therapeutic potential of combining these epigenetic modulators for the treatment of NSCLC.

Original languageEnglish
Pages (from-to)852-867
Number of pages16
JournalCancer Discovery
Volume7
Issue number8
DOIs
StatePublished - 2017
Externally publishedYes

Fingerprint

Dive into the research topics of 'Synergistic immunostimulatory effects and therapeutic benefit of combined histone deacetylase and bromodomain inhibition in non–small cell lung cancer'. Together they form a unique fingerprint.

Cite this